Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 69-72

  Casal, M ^a   Rodrigue F ^a   Johnson, B ^b   Garduno, E ^c   Tubau, F ^d   de Lejarazu, R Ortiz ^e   Tenorio, A ^e   Gimenez M J ^f   Bartolome R ^g   Garcia Rey, C ^h   Aguilar, L ^f   Garcia Escribano N ^h  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Division of Microbiology   (United States)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f SCHOOL OF MEDICINE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Broth microdilution; BSAC breakpoints; Etest

Indexed keywords

TIGECYCLINE;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; EPSILOMETER TEST; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; DIAGNOSTIC ERRORS; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SPAIN;

EID: 67249155698     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp169     Document Type: Article

References (10)

1. Karageorgopoulos DE, Kelesidis T, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
2. Pillar CM, Draghi DC, Dowzicky MJ et al. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008; 46: 2862-7.
3. Pascual A, Perea E, Alvarez M et al. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: A 5-year analysis. Diagn Microbiol Infect Dis 2007; 57: 195-200.
4. Camarena JJ, Zaragoza R, Navarro J et al. Actividad in vitro de tigeciclina frente Acinetobacter baumannii: Variaciones de CMIs por E-test dependientes del tipo de medio Mueller-Hinton II utilizado en rutina. Abstract 025. Enf Infect Microbiol Clin 2007; 25 Suppl. 58.
5. Fernández-Mazarrasa C, Mazarrasa O, Calvo J et al. High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol 2009; 47: 827-9.
6. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 177-8.
7. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-4.
8. British Society for Antimicrobial Chemotherapy. http://www.bsac.org.uk/ susceptibility_testing/breakpoints.cfm (21 January 2009, date last accessed).
9. Bolmström A, Karlsson A, Engelhardt A et al. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 2007; 45: 2474-9.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.